HUP0101372A2 - Triszubsztituált 1,3,5-triazin-származékok HIV-fertőzések kezelésére - Google Patents

Triszubsztituált 1,3,5-triazin-származékok HIV-fertőzések kezelésére

Info

Publication number
HUP0101372A2
HUP0101372A2 HU0101372A HUP0101372A HUP0101372A2 HU P0101372 A2 HUP0101372 A2 HU P0101372A2 HU 0101372 A HU0101372 A HU 0101372A HU P0101372 A HUP0101372 A HU P0101372A HU P0101372 A2 HUP0101372 A2 HU P0101372A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
amino
substituted
mono
Prior art date
Application number
HU0101372A
Other languages
English (en)
Inventor
Frederik Frans Desiré Daeyaert
Jan Heeres
Chih Yung Ho
Paul Adriaan Jan Janssen
Robert W. Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Bart De Corte
Marc René de Jonge
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP0101372A2 publication Critical patent/HUP0101372A2/hu
Publication of HUP0101372A3 publication Critical patent/HUP0101372A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya triszubsztituált 1,3,5-triazin-származékok HIV-fertőzések kezelésére. A találmány (I) általános képletű vegyületek N-oxidjai, gyógyá- szatilag elfogadható addíciós sói és sztereokémiaiizomer formáinak alkalmazására vonatkozik, ahol A jelentése CH, CR4vagy N; n étéke 0, 1, 2, 3 vagy 4; R1 és R2 jelentése egymástólfüggetlenül hidrogénatom, hidroxilcsoport, 1-12 szénatomos alkil-, 1-12 szénatomos alkoxi-, 1-12 szénatomos alkilkarbonil-, 1-12 szénatomosalkoxikarbonil-, aril-, amino-, mono- vagy di(1-12 szénatomos alkil)-amino-, mono- vagy di(1-12 szénatomos alkil)-aminokarbonilcsoport,ahol a fenti 1-12 szénatomos alkilcsoportok adott esetbenszubsztituálva lehetnek egy vagy két egymástól független hidroxil-, 1-6 szénatomos alkoxi-, hidroxi-(1-6 szénatomos alkoxi)-, karboxil-, 1-6szénatomos alkoxikarbonil-, ciano-, amino-, imino-, aminokarbonil-,aminokarbonilamino-, mono- vagy di(1-6 szénatomos alkil)amino-, aril-vagy Het csoporttal; vagy R1 és R2 együtt képezhet pirrolidinil-,piperidinil-, morfolinil-, azido-, mono- vagy di(1-12 szénatomosalkil)amino-(1-4 szénatomos alkilidén)-csoportot; R3 jelentésehidrogénatom, aril-, 1-6 szénatomos alkilkarbonil-, 1-6 szénatomosalkil-, 1-6 szénatomos alkoxikarbonil-, 1-6 szénatomos alkilcsoport,amely 1-6 szénatomos alkoxikarbonilcsoporttal van szubsztituálva; ésmindegyik R4 egymástól függetlenül lehet hidroxilcsoport, halogénatom,1-6 szénatomos alkil-, 1-6 szénatomos alkoxi-, ciano-, aminokarbonil-,nitro-, amino-, trihalogénmetil- vagy trihalogénmetoxicsoport; Ljelentése -X-R5 vagy -X-Alk-R6, ahol R5 és R6 egymástól függetlenüllehet indanil-, indolil- vagy fenilcsoport; ahol mindegyikszubsztituálva lehet; X jelentése -NR3-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- vagy -S(=O)2-; Alk jelentése 1-4 szénatomos alkándiilcsoport,az aril jelentése fenilcsoport vagy szubsztituált fenilcsoport; Hetjelentése telített vagy telítetlen heterociklusos csoport, ahol atelített heterociklusos csoport lehet pirrolidinil-, piperidinil-,homopiperidinil-, piperazinil-, morfolinil-, tetrahidrofuranil- vagytetrahidrotienilcsoport, amelyek mindegyike adott esetbenszubsztituálva lehet telítetlen aromás heterociklusos csoport lehetpirrolil-, furanil-, tienil-, piridinil-, pirimidinil-, pirazinil-vagy piridazinilcsoport, amelyek mindegyike adott esetben lehetszubsztituálva; gyógyszer előállítására, amellyel HIV-fertőzöttpáciensek kezelhetők. A találmány kiterjed továbbá az (I) általánosképletű vegyületek egy csoportjára is, amelyek új vegyületek, továbbáezek előállítására és az ezeket tartalmazó gyógyászati készítményekre. Ó
HU0101372A 1998-03-27 1999-03-24 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections HUP0101372A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7963398P 1998-03-27 1998-03-27
EP98201589A EP0945447A1 (en) 1998-03-27 1998-05-14 Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
PCT/EP1999/002044 WO1999050256A1 (en) 1998-03-27 1999-03-24 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections

Publications (2)

Publication Number Publication Date
HUP0101372A2 true HUP0101372A2 (hu) 2001-10-28
HUP0101372A3 HUP0101372A3 (en) 2003-02-28

Family

ID=22151790

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101372A HUP0101372A3 (en) 1998-03-27 1999-03-24 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections

Country Status (33)

Country Link
US (3) US6150360A (hu)
EP (2) EP0945447A1 (hu)
JP (1) JP2002511390A (hu)
KR (1) KR100593396B1 (hu)
CN (1) CN1157386C (hu)
AP (1) AP1475A (hu)
AR (1) AR018169A1 (hu)
AT (1) ATE295355T1 (hu)
AU (1) AU758624C (hu)
BG (1) BG64903B1 (hu)
BR (1) BR9909197A (hu)
CA (1) CA2324921C (hu)
DE (1) DE69925256T2 (hu)
DK (1) DK1066269T3 (hu)
EA (1) EA004540B1 (hu)
EE (1) EE200000535A (hu)
ES (1) ES2243056T3 (hu)
HK (1) HK1032394A1 (hu)
HR (1) HRP20000621A2 (hu)
HU (1) HUP0101372A3 (hu)
ID (1) ID26043A (hu)
IL (1) IL138670A (hu)
NO (1) NO317425B1 (hu)
NZ (1) NZ506787A (hu)
OA (1) OA11493A (hu)
PL (1) PL194660B1 (hu)
PT (1) PT1066269E (hu)
SI (1) SI1066269T1 (hu)
SK (1) SK14052000A3 (hu)
TR (1) TR200002761T2 (hu)
TW (1) TW570917B (hu)
WO (1) WO1999050256A1 (hu)
ZA (1) ZA200006042B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785360B1 (ko) 1999-09-24 2007-12-18 얀센 파마슈티카 엔.브이. 항바이러스 조성물
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US6645964B1 (en) * 1999-11-29 2003-11-11 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agent
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
US6887873B2 (en) * 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) * 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) * 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) * 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
EP1436266A4 (en) * 2001-09-21 2004-12-22 Reddy Us Therapeutics Inc METHOD AND COMPOSITIONS OF NEW TRIAZINE COMPOUNDS
AU2002342018A1 (en) * 2001-10-12 2003-04-28 New York University Trisubstituted triazines compounds with antitubulin activity
WO2003037346A1 (en) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US7375222B2 (en) * 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
US20070232572A1 (en) * 2003-02-07 2007-10-04 Aventis Pharma S.A. Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
MXPA05008368A (es) * 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
US6875781B2 (en) * 2003-04-04 2005-04-05 Cell Therapeutics, Inc. Pyridines and uses thereof
WO2005011702A1 (en) 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
US20070161637A1 (en) * 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
US7335770B2 (en) * 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
JP5031564B2 (ja) * 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
WO2006035067A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
RU2410379C2 (ru) 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
US7592451B2 (en) * 2005-06-23 2009-09-22 New York University Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
WO2007071199A1 (fr) * 2005-12-22 2007-06-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Composes de 2,4-disubstituee amido-6-substituee-[1,3,5]triazine ou de 1,3-pyrimidine, leurs procedes d'elaboration, et preparations pharmaceutiques les contenant et leurs utilisations
AU2007233737B2 (en) 2006-03-30 2012-11-29 Janssen Sciences Ireland Uc HIV inhibiting 5-amido substituted pyrimidines
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
MX2009007006A (es) 2006-12-29 2009-07-09 Tibotec Pharm Ltd Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.
JP6184866B2 (ja) 2010-10-27 2017-08-23 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 新規抗がん剤
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9914709B2 (en) * 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
WO2015144881A1 (en) * 2014-03-28 2015-10-01 Basf Se Diaminotriazine derivatives as herbicides
WO2017112951A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742466A (en) * 1956-04-17 Chx n nhx c c
US2671810A (en) * 1952-05-24 1954-03-09 Du Pont Long-chain diketones
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4096206A (en) 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
US4652645A (en) 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
EP0541966A3 (en) * 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) * 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
NZ274978A (en) 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
GB9519197D0 (en) * 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
CN1163401A (zh) * 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物

Also Published As

Publication number Publication date
ZA200006042B (en) 2001-10-26
HK1032394A1 (en) 2001-07-20
EP1066269B1 (en) 2005-05-11
JP2002511390A (ja) 2002-04-16
EA004540B1 (ru) 2004-06-24
NO20004809L (no) 2000-11-24
DE69925256T2 (de) 2006-02-23
AU758624C (en) 2004-03-11
WO1999050256A1 (en) 1999-10-07
PL343195A1 (en) 2001-07-30
BR9909197A (pt) 2000-12-05
ATE295355T1 (de) 2005-05-15
AU758624B2 (en) 2003-03-27
NZ506787A (en) 2003-02-28
BG104716A (en) 2001-04-30
SI1066269T1 (en) 2005-10-31
US20020115668A1 (en) 2002-08-22
DK1066269T3 (da) 2005-09-05
EP0945447A1 (en) 1999-09-29
AR018169A1 (es) 2001-10-31
BG64903B1 (bg) 2006-08-31
TR200002761T2 (tr) 2001-01-22
US6150360A (en) 2000-11-21
HUP0101372A3 (en) 2003-02-28
NO20004809D0 (no) 2000-09-26
CN1157386C (zh) 2004-07-14
CN1295566A (zh) 2001-05-16
OA11493A (en) 2004-05-07
SK14052000A3 (sk) 2001-06-11
PL194660B1 (pl) 2007-06-29
AP2000001913A0 (en) 2000-09-30
KR20010034270A (ko) 2001-04-25
TW570917B (en) 2004-01-11
ID26043A (id) 2000-11-16
KR100593396B1 (ko) 2006-06-28
US6774235B2 (en) 2004-08-10
US6372729B1 (en) 2002-04-16
CA2324921A1 (en) 1999-10-07
EE200000535A (et) 2002-04-15
IL138670A (en) 2005-12-18
PT1066269E (pt) 2005-09-30
EA200000993A1 (ru) 2001-04-23
CA2324921C (en) 2009-05-12
EP1066269A1 (en) 2001-01-10
NO317425B1 (no) 2004-10-25
ES2243056T3 (es) 2005-11-16
AP1475A (en) 2005-10-03
DE69925256D1 (de) 2005-06-16
AU3599799A (en) 1999-10-18
HRP20000621A2 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
HUP0101372A2 (hu) Triszubsztituált 1,3,5-triazin-származékok HIV-fertőzések kezelésére
HUP0101204A2 (hu) HIV-gátló pirimidinszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
HUP0401307A2 (hu) 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
HUP0102471A2 (hu) 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
NO331068B1 (no) Benzazepinderivater for behandling av nevrologiske forstyrrelser.
SE0104332D0 (sv) Therapeutic agents
HUP0102187A2 (hu) Azolo-triazinok és -pirimidinek, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HU9600278D0 (en) Remedy for nervous diseases
MY135841A (en) Novel benzodioxoles
HUP0401067A2 (hu) Defenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA04007470A (es) Piridinonas sustituidas.
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
NZ337121A (en) Pyrazine compounds as good anti-convulsants for the treatment of CNS diseases such as epilepsy
HUP0001848A2 (hu) NOS gátló 6-fenil-piridil-2-amin származékok
ES2150353A1 (es) Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
AU2002239463A1 (en) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
NO930143D0 (no) Piperidinforbindelser, deres fremstilling og bruk
MX2023009285A (es) Compuestos novedosos.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees